Broadening Horizons: Managing Diabetes with Centrally Acting Therapeutic Targets

Diabetes is a growing epidemic in the United States, affecting an estimated 30.3 million people, or nearly one-tenth of the population. Recently updated guidelines advocate the use of a wider range of treatments and combinations to individualize therapy for patients with type 2 diabetes (T2D). This calls for physicians to tailor patientspecific treatment plans by combining agents with complementary mechanisms of action to achieve and maintain glycemic control. In addition, patients with T2D are at high risk for atherosclerotic cardiovascular (CV) complications. Therefore, antihyperglycemic agents that not only improve hyperglycemia but also reduce CV risk are desirable. In this live symposium, experts in the field of diabetes will review the role of centrally acting medications in the treatment of T2D.


Please Note: this course is housed on Medscape. Upon selecting 'Take Course,' you will be redirected to Medscape to complete the activity.

Target Audience

This activity is intended for diabetologists and endocrinologists.

Learning Objectives

Upon completion of this activity, learners will:

• Have increased knowledge regarding the
– Mechanism of action of centrally acting treatments for diabetes
– Role of centrally acting pharmacologic therapy in diabetes management
– Patient education points related to bromocriptine and diabetes treatment

• Have greater competence related to
– The use of a comprehensive management plan for patients with diabetes
– The appropriate use of centrally acting pharmacologic therapy as part of an individualized diabetes management plan

Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Course summary
Available credit: 
  • 1.25 AMA
  • 1.25 Attendance
Course opens: 
08/23/2018
Course expires: 
08/23/2019
Cost:
$0.00

CHAIR


Lawrence Blonde, MD
Director
Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, Louisiana


PANELISTS


Samuel Dagogo-Jack, MD
A.C. Mullins Professor in Translational Research
Professor of Medicine and Chief
Division of Endocrinology, Diabetes and Metabolism
Director, General Clinical Research Center
University of Tennessee Health Science Center
Memphis, Tennessee


Aaron Vinik, MD, PhD
Murray Waitzer Endowed Chair for Diabetes Research
Professor of Medicine, Pathology, Neurobiology
Director of Research and Neuroendocrine Unit
Eastern Virginia Medical School
Strelitz Diabetes Center
Norfolk, Virginia

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.25 AMA
  • 1.25 Attendance

Accreditation Period

Course opens: 
08/23/2018
Course expires: 
08/23/2019

Price

Cost:
$0.00
Please login or register to take this course.